ReaGene Biosciences (https://www.reagenebiosciences.com/) a group company of start-up ReaGene Innovations Pvt Ltd incubated at Aspire-BioNEST University of Hyderabad received the best Emerging bio-incubator 2021 award from BIRAC and was identified as an emerging start-up company by an independent jury panel of ChemTech- Biopharma conference 2021.
The award was in recognition of the unique 3D models being developed by the group companies. These models are focused on discovery of new products for high value unmet diseases such as sepsis and COVID-19. To date, majority of preclinical research is conducted in animals for both efficacy and toxicity, however, proved to be poorly translated to clinical outcomes. There is a strong need for better translational models to improve clinical translation and decrease clinical attrition rates. Currently used in vitro human single-cell static models do not mimic human physiology, cell-cell and organ-organ communications those play important role in drug efficacy and toxicity in humans in vivo.
ReaGene mission is to build proprietary Humanized 3D tools containing multiple cell types of different organs to allow communications of different cell types and organs. These models represent closest to human in vivo condition recapitulating human physiology to measure efficacy and toxicity simultaneously and make informed decisions on clinical liabilities before moving drugs into clinical trials. These models are much superior to organoids and spheroids to mimic human physiology and communications.
The founders of ReaGene, Dr. Uday Saxena an alumnus of the University of Hyderabad and Dr. Subrahmanyam Vangala expressed their happiness at the recognition and are hopeful that these proprietary disruptive 3D bio printing platforms will revolutionize drug discovery research in India and rest of the world. Both founders each have nearly 30 years of extensive experience in big pharma companies including Pfizer, Wyeth, JNJ, Purdue Pharma and Reddy Labs in innovative drug discovery and drug development research.
ReaGene has ongoing collaborations with Tech Mahindra, Issar Pharma, ProdigY on Sepsis and COVID projects using human vascular 3D lung model. Their larger mission is to apply these tools to elucidate disease pathways, identify novel drug targets, biomarkers, and discover novel drugs or repurpose other drugs on market. In 2019, ReaGene Biosciences was awarded prestigious “Promising Entrepreneurs of India” by Economic Times of India. ReaGene will continue to conduct Bench to Bedside cutting edge innovative research to help patients in India and rest of the world.
